瑞巴派特治疗NSAIDs相关性肠病疗效的Meta分析

目的 评价瑞巴派特治疗非甾体抗炎药(nonsteroidal anti-inflammatory drugs,NSAIDs)相关性肠病的临床疗效。方法 计算机检索PubMed、MedLine、Embase、The Cochrane Library、中国生物医学文献数据库、中国知网和万方数据库发表的有关瑞巴派特治疗NSAIDs相关性肠病的随机对照试验。设定时间期限为各数据库建库至2021年6月。依据Cochrane系统评价指导手册推荐的评价标准对纳入研究进行质量评价,对文献主要的结局指标数据录入后采用 Review Manager 5.3软件进行Meta分析。结果 最终研究纳入符合条件的随机对照试验6个,研究对象共纳入255例;3篇主要对瑞巴派特治疗后肠道损伤例数进行观察,均可提取有效数据;4篇观察了治疗后肠黏膜糜烂数,均可提取有效数据;3篇观察了治疗后肠黏膜溃疡数,均可提取有效数据;将全部结局指标数据录入后,经Meta分析结果显示,与常规方案组治疗NSAIDs相关性肠病比较,瑞巴派特组肠道损伤的例数减少(OR=0.34,95%CI为0.15~0.75,P<0.05);肠黏膜糜烂数明显减少(MD=-4.71,95%CI为-6.40~-3.02,P<0.05);肠黏膜溃疡数明显减少(MD=-0.45,95%CI为-0.89~-0.01, P<0.05)。结论 瑞巴派特在预防和治疗NSAIDs相关性肠病方面具有优势,可以减轻服用NSAIDs药物患者的肠道损伤。

Rebamipide in the treatment of nonsteroidal anti-inflammatory drug-associated intestinal disease: A meta-analysis

Objective To evaluate the clinical efficacy of Rebamipide in the treatment of nonsteroidal anti-inflammatory drugs (NSAIDs)-associated intestinal disease. Methods PubMed, MedLine, Embase, The Cochrane Library, China Biomedical Literature Database (CBM), CNKI and Wanfang Data were searched for randomized controlled trials(RCTs)in the treatment of NSAIDs-associated bowel diseases. Set a time limit for each database to be built until January 2021. According to the evaluation criteria recommended by the Cochrane system evaluation guide manual, the quality of the included study was evaluated, and Review Manager 5.3 software was used for Meta analysis after entering the main outcome indicators of the literatures. Results Finally, eligible 6 RCTs were included, with a total of 255 subjects; 3 articles mainly observed the number of cases of intestinal injury after treatment with Rebamipide, and all of them could extract effective data; the effective data could be extracted from 4 articles focused the number of intestinal mucosal erosion after treatment, 3 articles observed the number of intestinal mucosal ulcers after treatment with extracted effective data. The results of Meta analysis showed that the number of intestinal injuries (OR=0.34, 95%CI: 0.15-0.75, P<0.05), intestinal mucosal erosion(MD=-4.71, 95%CI:-6.40 to -3.02, P<0.05) and intestinal mucosal ulcers (MD =-0.45, 95% CI: -0.89 to -0.01, P<0.05) decreased significantly in the Rebamipide group as compared to the routine regimen group. Conclusion Rebamipide has advantages in the prevention and treatment of NSAIDs-associated intestinal disease and can reduce intestinal injury in patients who take NSAIDs drugs for a long time.